# Enzyre

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enzyre-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Netherlands
- Website: www.enzyre.com
- Total disclosed funding: $12M
- Latest round: Series A (Nov 2, 2022)
- Investors on record: 5

## About

Based in the Netherlands, and founded in 2016, Enzyre B.V. provides blood coagulation management technology. In November 2022, the firm raised EUR 12 million in Series A funding from investors DEMCON, i&i Biotech Fund, and Oost NL, with participation from returning investors Novalis Biotech, and Takeda Ventures. As of 2022, the company is headed by Guido Maertens.

The company offers a healthcare platform that engages in developing a device that could approach hemophilia patients. It offers a product called ENZYPAD which is a handheld micro-laboratory that helps in monitoring the blood coagulation status of any patient anywhere. The ENZYPAD processors carry ENZYCARDs which are small microfluidic cartridges that contain all the reagents and controls to perform up to sixteen reactions.

The company plans to use the November 2022 funding to support further development of its product and clinical trials.

## Funding rounds

- Series A, Nov 2, 2022, $12M — Oost NL, Takeda Ventures, DEMCON, Novalis Biotech, i&i Bio

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- DEMCON — Series A
- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Series A
- i&i Bio (https://capitalatlas.ai/funds/i-i-bio) — Series A